Evotec Earnings Call: Biologics Surge Amid Tough Reset

Evotec Ag (Adr) ((EVO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Evotec’s latest earnings call painted a picture of cautious optimism, as management highlighted a transformational pivot driven by Just‑Evotec Biologics and substantial cost savings. At the same time, they were frank about ongoing weaknesses in Discovery & Preclinical Development and acknowledged that 2026 will be a transition year with near‑term pressure before structural improvements fully show through.

Solid Q4 Growth Masks a Tough Full Year

Group revenues in Q4 2025 rose by EUR 32.1m, or 14.5%, to EUR 253.3m, and on a constant‑currency basis the increase was about 21%, signaling clear momentum late in the year. Yet for the full year, group revenues slipped 1.1% to EUR 788.4m, underscoring how difficult the 2025 backdrop was despite a strong finish.

Just‑Evotec Biologics Emerges as the Growth Engine

Just‑Evotec Biologics (JEB) was the standout performer, with Q4 revenues doubling, up EUR 59.4m or 104.2%, and full‑year revenues climbing nearly 40% to EUR 259.4m. Profitability followed suit as adjusted EBITDA for JEB jumped roughly 443% to EUR 53.2m, confirming the biologics unit as Evotec’s primary profit driver.

Sandoz Deal Unlocks Long‑Term Biologics Upside

A landmark agreement with Sandoz, closed in December 2025 and valued at $650m plus future royalty potential on 10 biosimilars, underscores the commercial leverage of Evotec’s platform. While the company expects royalties only after 2028, management stressed that platform‑derived revenues from the deal should contribute meaningfully over time.

Balance Sheet Strength Supports the Transformation

Evotec closed the year with cash liquidity of EUR 476m and a net cash position, giving the company a solid buffer to navigate volatility. Management also emphasized that the firm entered 2026 without active financial covenants, boosting financial flexibility to execute on its Horizon transformation plan.

Horizon Program Drives Structural Cost Savings

The company reported more than EUR 60m in annualized cost savings achieved in 2025 and unveiled the broader Horizon transformation targeting about EUR 75m in structural run‑rate savings by end‑2027. Roughly 20–30% of these savings are expected to materialize already in 2026, laying the groundwork for higher mid‑term margins.

Group EBITDA Improves Despite Mixed Revenue Trends

Adjusted group EBITDA in Q4 2025 climbed to EUR 58.0m, more than doubling year on year with a EUR 29.5m increase, while full‑year adjusted EBITDA rose 81.9% to EUR 41.1m. Management linked this margin improvement primarily to JEB’s breakout performance and tighter cost discipline across the group.

Portfolio Monetizations Generate Cash and Optionality

Evotec continued to monetize parts of its EVOequity portfolio, including selling a minority stake in Dark Blue Therapeutics for around EUR 13m upfront. In addition, the announced sale of the Toulouse site is expected to deliver roughly EUR 100m upfront plus contingent milestones exceeding EUR 150m, illustrating the potential of non‑core asset sales to fund growth.

Diversifying JEB Beyond Sandoz and DoW

Non‑Sandoz and non‑Department of Defense customers at JEB grew more than 60% in 2025, a key step in reducing concentration risk. Management expects this broader customer base to represent about 50% of Just revenue by end‑2026, up from roughly 30% in 2025, helped by new grants such as the BioMaP award and Gates Foundation‑backed projects.

Discovery & Preclinical Development Remains Under Pressure

The Discovery & Preclinical Development segment suffered a sharp setback, with Q4 revenues falling 16.6% to EUR 137.1m and full‑year revenues dropping 13.5% to EUR 528.9m. Profitability deteriorated as adjusted EBITDA for the unit slid to EUR 6.8m in Q4 and to a loss of EUR 12.0m for the year, reflecting lower volumes and internal overcapacity.

Biotech Funding Weakness Weighs on Demand

Management pointed to persistent softness in early‑stage biotech funding and drug discovery markets as the main drag on D&PD, curbing client demand and delaying new projects. These external headwinds make it harder to fully utilize existing capacity and are a key reason Evotec is restructuring certain sites and cost bases.

One‑Off Sandoz License Payment Skews Comparisons

Q4 2025 benefited from a roughly EUR 65m license payment from Sandoz that will not repeat in 2026, inflating the prior‑year baseline. Management stressed that the absence of this one‑off payment is a major factor behind more subdued 2026 revenue and earnings visibility and reinforces the message that 2026 will be a transition year.

DoD and Currency Headwinds Add to the Drag

Revenues tied to U.S. Department of Defense‑related activities fell in the second half of 2025 due to budget cuts, further weighing on group performance. Foreign exchange also hurt results by about 2.8% in 2025, and Evotec expects an even larger FX headwind of roughly 3.5% to revenues in 2026.

Restructuring via Site Consolidation and Job Cuts

Under the Horizon program, Evotec plans to reduce its global footprint from 14 to 10 sites and cut around 800 positions, including closures in Abingdon, Munich, Lyon, and Framingham. Management argued that these steps are necessary to tackle overcapacity and restore profitability, while acknowledging some execution risk and potential disruption for customers and talent.

Guidance Signals a Transitional 2026 Before Reacceleration

For 2026, Evotec guided group revenues to about EUR 700–780m, or EUR 730–810m at constant FX, and adjusted EBITDA of roughly EUR 0–40m, or EUR 10–50m at constant FX, with a 3.5% FX headwind. Management expects a weaker first half and improving second half as 20–30% of Horizon savings and an estimated EUR 20m EBITDA uplift from removing Toulouse’s cost drag take effect, alongside roughly 40% growth in JEB non‑Sandoz/non‑DoD activities and a modest recovery in D&PD.

Evotec’s earnings call ultimately framed 2025 as the year biologics took the growth baton while legacy discovery activities faltered, forcing a structural reset. Investors are now being asked to look through a challenging 2026, trusting that cost savings, a stronger JEB mix, and portfolio monetizations will position the company to reach its longer‑term revenue and margin ambitions by the end of the decade.